Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

800-Patient registry aims to unlock secrets of heart shock survival

NCT ID NCT07597291

Knowledge-focused Sponsor: Hospital de Santa Cruz, Portugal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study follows 800 adults admitted to a cardiology department with cardiogenic shock, a life-threatening condition where the heart suddenly can't pump enough blood. Researchers will review medical records from 2017 onward to see how treatments and survival rates have changed. Participants receive standard care, and their data is collected for up to one year. The goal is to identify which management strategies lead to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could reveal which management strategies improve survival for cardiogenic shock patients.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients admitted with cardiogenic shock. The population reflects a real-world, highly complex, and critically ill cohort comprising both a retrospective cohort (admitted from January 2017 onwards) and a prospective cohort consecutively enrolled at the center.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Cardiogenic shock according to the following criteria: Cardiac disorder resulting in hypotension, defined as at least one of the following: * Systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or * Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg AND Evidence of tissue hypoperfusion, defined by the presence of at least one of the following: * Serum lactate \>2 mmol/L * Acute kidney injury and/or oliguria * Acute hepatic injury * Cool or mottled extremities * Altered mental status AND Clinical presentation judged to be primarily attributable to a cardiac etiology. Exclusion Criteria: * Age \< 18 years. * Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock). * Refusal to participate in the study (applicable only to the prospective cohort).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock myocardial infarction Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock Cardiogenic shock acute Cardiogenic shock post myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unidade Local de Saúde de Lisboa Ocidental

    RECRUITING

    Carnaxide, Lisbon District, 2790-134, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.